Caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in patients with human immunodeficiency virus infection

OBJECTIVES: The effectiveness of trimethoprim/sulfamethoxazole (TMP/SMZ) for pneumocystis pneumonia (PCP) is limited with adverse events. Caspofungin, by inhibiting the cyst form of Pneumocystis jirovecii, may be an alternative therapy for PCP. However, the availability of clinical data about caspof...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Q, Si, J, Jiang, F, Xu, R, Wei, B, Huang, B, Li, Q, Jiang, Z, Zhao, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984216/
https://www.ncbi.nlm.nih.gov/pubmed/33277811
http://dx.doi.org/10.1111/hiv.13013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984216/
https://www.ncbi.nlm.nih.gov/pubmed/33277811
http://dx.doi.org/10.1111/hiv.13013

Ejemplares similares